wqrking 2020-01-17 10:48 IP:西安
標(biāo)的公司基本要求:國(guó)內(nèi)具有生產(chǎn)研發(fā)銷(xiāo)售資質(zhì)藥企(產(chǎn)品不含醫(yī)療器械);地理位置處于珠三角、長(zhǎng)三角、江浙、深圳、西安市地區(qū);資產(chǎn)狀況良好,經(jīng)營(yíng)正常;年度營(yíng)收在5000萬(wàn)到1.5億之間,凈利在500萬(wàn)到800萬(wàn)之間,熟悉一致性評(píng)價(jià)工作程序。   [更多]
懸賞
¥90.00
已托管
載入中...
白嬌 2020-01-07 08:42 IP:未知
1.懸賞2013年1月1日之后NMPA批準(zhǔn)的藥品注冊(cè)信息 2.必須提供完整信息,以附件形式提交 3.核實(shí)后如果正確,每個(gè)獎(jiǎng)勵(lì)30元 4.投稿時(shí)請(qǐng)隱藏提交 5.請(qǐng)勿在百度上直接搜索 6.需是藥智網(wǎng)未收集的數(shù)據(jù)   [更多]
懸賞:
懸賞
¥300.00
已托管
載入中...
a28179 2019-12-30 16:48 IP:重慶
①文獻(xiàn)和網(wǎng)站來(lái)源必須權(quán)威、專(zhuān)業(yè),盡量找外文或官網(wǎng)的文獻(xiàn)或報(bào)道,不能是百度百科等; ②簡(jiǎn)要綜述的語(yǔ)句具有邏輯性和連貫性。 ③由于藥物本身存在信息不全或難找到信息源,以及藥物綜述質(zhì)量不定(如翻譯質(zhì)量不定等)的情況,賞金酌情給出,請(qǐng)諒解。 ④以300個(gè)藥物對(duì)象為單位,價(jià)格300元。有意者請(qǐng)聯(lián)系本人,再提供于您相關(guān)文件。如果合作順利,期望長(zhǎng)期合作。 具體要求詳見(jiàn)文件夾中的Word文檔,藥物對(duì)象詳見(jiàn)文件夾中的Excel表。   [更多]
懸賞:
懸賞
¥900.00
已托管
載入中...
Like2291 2019-12-18 15:59 IP:重慶
1、Przemysl Chemiczny, 85(5), 349-350; 2006 2、Polymorphism of sodium valproate 【作 者】Mifsud, H.;Miguel, L.;Lavastre, V.;Maire, G. 【刊 名】Calorim. Anal. Therm. 【出版日期】1993 【卷 號(hào)】Vol.24 【頁(yè) 碼】309-312 3、Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC 4、[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group] 5、Ital J Gastroenterol. 1995 Sep;27(7):376-7. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U1, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer G. Author information 6、AJHYA2 American Journal of Hygiene. (Baltimore, MD) V.1-80, 1921-64. For publisher information, see AJEPAS. Volume(issue)/page/year: 76,209,1962   [更多]
懸賞
¥60.00
已托管
載入中...
leoncpu 2019-12-16 10:59 IP:資陽(yáng)
我司計(jì)劃以MAH委托CMO方式,進(jìn)行數(shù)個(gè)固體制劑項(xiàng)目的申報(bào)與注冊(cè)申報(bào)后的委托生產(chǎn),現(xiàn)詢(xún)川渝兩地的GMP車(chē)間進(jìn)行項(xiàng)目合作: 要求:1. 有較為完善的GMP質(zhì)量體系并通過(guò)新版GMP認(rèn)證,并有意進(jìn)行化藥固體制劑CMO合作; 2. 化藥固體制劑車(chē)間,配備流化床(制粒用)、混合機(jī)、壓片機(jī)、包衣機(jī)等設(shè)備及相應(yīng)的技術(shù)與生產(chǎn)操作人員; 3. 公司有一定的產(chǎn)品研發(fā)注冊(cè)經(jīng)驗(yàn); 4. 成都周邊藥企優(yōu)先。 5. 需要提供受托方主要負(fù)責(zé)人的職位及手機(jī)號(hào),必須保證信息的真實(shí)性和可靠性,電話溝通驗(yàn)證真實(shí)性后給予報(bào)酬。   [更多]
懸賞:
懸賞
¥200.00
已托管
載入中...
Like2291 2019-12-11 14:07 IP:重慶
1、Arzneimittelforschung. 1985;35(7A):1203-8. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. 2、Arzneimittelforschung. 1985;35(7A):1149-54. K Kawamura, K Watanabe, Y Kimura. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation 3、Gel formation of cefpodoxime proxetil 4、Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis. GK Webster, RG Bell - Journal of AOAC International, 1999 - europepmc.org 5、Rydell N, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.Ⅵ. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of the arthritis in track horses. Acta Vet Scand, 1970,11:139~146 6、Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol, 1974, 22:731~736 7、Weiss C, Balazs EA, St Onge R, et al. Clinical studies of the intra-articular injection of Healon in the treatment of osteoarthritis of human knee. Semin Arhtritis Rheum, 1980, 11(Suppl 1):143~144 8、Punzi L, Schiavon F, Ramonda R, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and non-inflammatory knee diffusions. Curr Ther Res, 1988, 43:643~647 9、Nolan JP, reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice, 2007 10、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]
懸賞
¥50.00
已托管
載入中...
冬候鳥(niǎo)斯伯格 2019-12-05 10:46 IP:重慶
收集了全國(guó)各省市的藥品中標(biāo)信息,為了保證給大家有更準(zhǔn)確及時(shí)的信息,需要 對(duì)藥品中標(biāo)信息數(shù)據(jù)庫(kù)及時(shí)更新,現(xiàn)請(qǐng)人進(jìn)行最新中標(biāo)數(shù)據(jù)的收集整理。 工作內(nèi)容:及時(shí)查到最新公布的藥品中標(biāo)信息,并將最新的文件按指定要求 處理成規(guī)范的格式(excel表)。交稿如發(fā)現(xiàn)遺漏,反饋后望及時(shí)補(bǔ)充。 補(bǔ)充月份:2019年8月-2020年1月(共6個(gè)月)   [更多]
懸賞
¥3408.00
已托管
載入中...
Like2291 2019-11-22 16:00 IP:重慶
1、Clinical Features and Molecular Genetics of HSD387 Deficiency and AKRlD1 Deficiency A case report of inborn errors of bile acid synthesis 2、3B-hydroxy-△5-C27 steroid dehydrogenase deficiency: a case report 3、Hallas G. Chem. and Ind. 1972,691 4、Chemical and biological characterization of iron-protein succinylate (ITF 282)' 5、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]
懸賞
¥50.00
已托管
載入中...
Like2291 2019-11-15 17:51 IP:重慶
1、targeting inhaled steroids 文獻(xiàn) 2、Minerva Dietol Gastroenterol. 1989 Jul-Sep;35(3):175-89. [A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. [Article in Italian] Del Tacca M, Danesi R, Blandizzi C, Bernardini MC. 3、See 1 citation found by title matching your search: J Pharmacol. 1985;16 Suppl 2:145-69. [MI cholinergic receptors of gastric secretion: current status]. [Article in French]、 4、Carrigan PJ, Papp K, Schulz G, Venable T. Bioavailability of valproate from divalproex sodium tablets. Abbott Laboratories, North Chicago, IL (unpublished data). 5、MITOXANTRONE - MECHANISM OF ACTION, ANTITUMOR-ACTIVITY, PHARMACOKINETICS, EFFICACY IN THE TREATMENT OF SOLID TUMORS AND LYMPHOMAS, AND TOXICITY,文獻(xiàn) 6、American Journal of Kidney Diseases Volume 70, Issue 6, December 2017, Pages 737-751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)   [更多]
懸賞
¥60.00
已托管
載入中...
Like2291 2019-11-08 09:46 IP:重慶
1、Nimesulide - a non-steroidal anti-inflammatory drug, a preferential cyclooxygenase-2 inhibitor 【出處】Vutreshni bolesti. 2000;32(1):33-6. 2、Bioequivalence study between two slow release batches ofindapamide SR 1.5 mg with different dissolution pro- files after repeated oral administration over 7 days in 12 healthy volunteers: a randomised double blind cross over study. Fulmer Hall, UK: Servier, 1993. Report No.: NP 910 3、Schiavi P, Jochemsen R, Hiley M, et al. Pharmacokinetics ofslow and immediate release formulations of indapamide after single oral administration under fasting conditions and after food, in healthy volunteers. Eur J Drug Metab Pharmacokinet 1996; Spe- cial Issue: 42 4、找一篇97年的政策法規(guī)文件,標(biāo)題:國(guó)家醫(yī)藥管理局國(guó)藥字(97)253號(hào)文件 5、Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder. Jpn J Clin Psychopharmacol 2009;12:1613-1634   [更多]
懸賞
¥50.00
已托管
載入中...
發(fā)布需求,坐等藥智客上門(mén)
  • 安全可靠,先驗(yàn)收再正式付款
  • 性?xún)r(jià)比超高,節(jié)省一半費(fèi)用
  • 80%的需求得到了圓滿解決
立即發(fā)布需求

推薦任務(wù)